

HEXIMA LIMITED

ASX ANNOUNCEMENT



2 December 2021

MARILYN ANDERSON STEPS DOWN FROM BOARD

Decision a reflection of the positive evolution of the Company

MELBOURNE, AUSTRALIA (2 December 2021): Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing pezadeftide (formerly HXP124), as a potential new prescription topical treatment for onychomycosis, today announces that Marilyn Anderson, current Executive Director, will resign her Board seat effective as of today. Marilyn will continue in the role of Chief Science Officer.

Professor Jonathan West, Chairman of the Board thanked Marilyn for her long service to the Company. "Marilyn is a founder of Hexima and the driving force behind our many innovations and discoveries in peptide science, both in agricultural applications and in our new human pharmaceutical technologies.

"With the Company moving into a more advanced stage in its growth and now approaching phase III clinical trials, Marilyn has indicated her wish to step aside and support a more commercially oriented international Board."

Marilyn Anderson said "I have enjoyed my tenure on the Board at Hexima and supporting the Company as it has moved from discovery to the development of a product with great potential. Hexima is a great company with a very talented and motivated staff and a board with the international commercial experience that we need to take our product to market. I have, every confidence in its future and look forward to my continued involvement as a member of the executive team."

This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & CEO

Enquiries:

Dr Nicole van der Weerden
Chief Operating Officer
n.vanderweerden@hexima.com.au

To join our email database and receive company announcements please [click here](#)

ABOUT HEXIMA

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on [Twitter](#) and [LinkedIn](#) or email us at info@hexima.com.au.